Bisphosphonates and receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitors are bone-modulating agents with antiresorptive effects used in both osteoporotic and metastatic cancer patients to improve bone strength and prevent fractures. Here, TNFSF11 is linked to metastatic malignant neoplasm.